Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Tagawa

Showing results (321-330 of 354) with videos related to

Pageof 36
Sort By:
Nature Communications|July 7, 2019
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signalingBrian D Robinson, Panagiotis J Vlachostergios, Bhavneet Bhinder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2023
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate CancerLisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated AntigensNeal D Shore, Matthew P Morrow, Trevor McMullan, et al.
World Journal of Urology|July 27, 2012
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?Michael Rink, Shahrokh F Shariat, Evanguelos Xylinas, et al.
Cancer Discovery|January 10, 2024
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationGian Marco Franceschini, Orsetta Quaini, Kei Mizuno, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
BJU International|September 24, 2013
Predictors of survival in patients with disease recurrence after radical nephroureterectomyLuis A Kluth, Evanguelos Xylinas, Matthew Kent, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
BJU International|September 4, 2012
Predictors of cancer-specific mortality after disease recurrence following radical cystectomyMichael Rink, Daniel J Lee, Matthew Kent, et al.
European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.
Pageof 36

Showing results (321-330 of 354) with videos related to

Sort By:
Pageof 36
Nature Communications|July 7, 2019
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signalingBrian D Robinson, Panagiotis J Vlachostergios, Bhavneet Bhinder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2023
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate CancerLisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated AntigensNeal D Shore, Matthew P Morrow, Trevor McMullan, et al.
World Journal of Urology|July 27, 2012
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?Michael Rink, Shahrokh F Shariat, Evanguelos Xylinas, et al.
Cancer Discovery|January 10, 2024
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationGian Marco Franceschini, Orsetta Quaini, Kei Mizuno, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
BJU International|September 24, 2013
Predictors of survival in patients with disease recurrence after radical nephroureterectomyLuis A Kluth, Evanguelos Xylinas, Matthew Kent, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
BJU International|September 4, 2012
Predictors of cancer-specific mortality after disease recurrence following radical cystectomyMichael Rink, Daniel J Lee, Matthew Kent, et al.
European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.
Pageof 36